SCHEMBL10287635

SCHEMBL10287635

CC1(C)CN(CCCC2c3cc(OCCN4CCOCC4)ccc3OCc3ncccc32)CCC1(O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 2/20 0.49
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
EPHX2 P34913 3/20 0.35
ALDH1A1 P00352 1/20 0.35
DRD2 P14416 5/20 0.34
SLC6A4 P31645 2/20 0.34
HTR1A P08908 1/20 0.34
DRD1 P21728 1/20 0.34
DRD5 P21918 1/20 0.34
SLC6A2 P23975 1/20 0.34
HTR2A P28223 1/20 0.34
HTR7 P34969 1/20 0.34
HRH1 P35367 1/20 0.34
DRD3 P35462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL656521 0.82 CCR1 (0.72) CCR1CNR1CNR2GPR55KDM4E
SCHEMBL656522 0.82 CCR1 (0.72) CCR1CNR1CNR2GPR55KDM4E
SCHEMBL14580314 0.82 CCR1 (0.72) CCR1CNR1CNR2GPR55KDM4E
SCHEMBL655349 0.73 CCR1 (0.75) CCR1NPC1ALDH1A1DRD2SLC6A4
SCHEMBL656546 0.73 CCR1 (0.75) CCR1KDM4ENPC1ALDH1A1DRD2
SCHEMBL14580040 0.73 CCR1 (0.53) CCR1CNR1CNR2GPR55KDM4E
SCHEMBL655350 0.73 CCR1 (0.75) CCR1NPC1ALDH1A1DRD2SLC6A4
SCHEMBL13620877 0.73 CCR1 (0.75) CCR1KDM4ENPC1ALDH1A1DRD2
SCHEMBL656545 0.73 CCR1 (0.75) CCR1KDM4ENPC1ALDH1A1DRD2
SCHEMBL14703482 0.73 CCR1 (0.75) CCR1NPC1ALDH1A1DRD2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046311-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF KYOWA HAKKO KOGYO CO., LTD. (JP) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046311-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF ACKR3, CCR2, CXCR2 CCR1 9/4885CNR1 152/4885CNR2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.